Source: European Medicines Agency (EU) Revision Year: 2026 Publisher: GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland, D24 YK11
Lynavoy 40 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Purple, round, biconvex film-coated tablets (9 mm in diameter), debossed with "GS 3JG" on one side. |
Each film-coated tablet contains 40 mg linerixibat.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Linerixibat is a locally acting, minimally absorbed reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids in the ileum leading to increased faecal elimination. Linerixibat improves pruritus in PBC patients which is assumed to be due to a decrease in mediators of pruritus including serum bile acids, lysophosphatidic acid (LPA) [via measurement of autotaxin as a surrogate] and interleukin 31 (IL-31). |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose (E460) Tablet coating: Hypromellose (E464) |
Opaque, white high-density polyethylene (HDPE) bottles with polypropylene child-resistant closures and polyethylene induction heat seal liner, containing a HDPE canister with silica gel desiccant.
Pack sizes available:
Not all pack sizes may be marketed.
GlaxoSmithKline Trading Services Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland, D24 YK11
EU/1/26/2053/001-003
| Drug | Countries | |
|---|---|---|
| LYNAVOY | Lithuania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.